Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 11/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805909 | 0.91 | SCN9A (0.65) | TRPV3SCN9A | |
| SCHEMBL30755490 | 0.83 | TRPV3 (0.54) | TRPV3SCN9A | |
| SCHEMBL27371412 | 0.83 | TRPV3 (0.54) | TRPV3SCN9A | |
| SCHEMBL5735975 | 0.83 | TRPV3 (0.51) | TRPV3 | |
| SCHEMBL3721067 | 0.83 | TRPV3 (0.54) | TRPV3SCN9A | |
| SCHEMBL4592336 | 0.83 | TRPV3 (0.54) | TRPV3SCN9A | |
| SCHEMBL4831269 | 0.83 | TRPV3 (0.54) | TRPV3SCN9A | |
| SCHEMBL9009141 | 0.81 | THRB (0.53) | TRPV3SCN9A | |
| SCHEMBL30484292 | 0.81 | THRB (0.53) | TRPV3SCN9A | |
| SCHEMBL21236834 | 0.80 | SCN9A (0.62) | TRPV3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| CN-101213186-A | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-07-02 | — | — | CN | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | TRPV3 920/4885SCN9A 1166/4885TOP1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.